Sa!Vy Diary (L.H.C.) - La Stock Del XXXIV Secolo !!!

IMO-Holdings.

I.M.O.

... in my opinion ....



Si postano alcune risorse chiave per l'analisi di IMO
una pietra miliare nel gergo borsistico dei FoLers
e nuova conglomerata pan-continentale multi-services.




chart.ashx

chart.ashx

chart.ashx





Maritime & Shipp Services

Web-Company

New Millennium Medicine

Aereospace

Governative Agency of Nigeria

Coffeeman trading station

Advanced Mathematical Recruiting

Susteinable Commerce

Italian Food

Industrial Electronic Sector

Adult & Sex Services

Global Healthcare

N. Europe Pharma Services

Urban Vehicle Solutions

Car Services

Mechanical Components

Social Network

Mathematical Resources

New World Sounds (Jungle, Drumm'N'Bass, H.Core)






N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
Ultima modifica:
Astm.

$@!V€ A TUTTI.

Chart ema-format: price replaced by exp.mov.aver. in daily frame 5/10/20 (thin-lines); in bold-lines three simple moving averages (daily 50/200/500).
Chart two envelopes-format: two-envelopes method, with short-term envelopes in blu vs. long-term envelopes in red; price in daily-close.
Chart monthly-candles-format: price as candles in monthly frame.
Chart daily-candles-format: price as candles in daily frame with main simple moving averages.


ASTM - pure player
sub-sector: stem (adult-marrow); C.N.S., heart, circulatory-sist., bone

Site
http://www.aastrom.com/
Aastrom Biosciences, Inc. [Domino's Farms, Lobby K, 24 Frank Lloyd Wright Drive, Ann Arbor MI 48105], incorporated in March 1989, is a regenerative medicine company and focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on its Tissue Repair Cell (TRC) technology. The Company’s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations and are investigated for their ability to aid in the regeneration of tissues, such as cardiac, vascular and bone.
TRC-based products have been used in over 350 patients, and its stages of development are Cardiac regeneration includes Cardiac Repair Cells (CRCs); Dilated cardiomyopathy (DCM) (severe heart failure); Vascular regeneration includes Vascular Repair Cells (VRCs); Critical limb ischemia (CLI); Bone regeneration includes Bone Repair Cells (BRCs); Osteonecrosis of the femoral head; Non-union fractures, and Maxillofacial.
The Company’s platform TRC technology is based on autologous cell products, which are a cell mixture containing large numbers of stem and early progenitor cells produced outside of the body from a small amount of bone marrow taken from the patient, and the ability to produce these products in an automated process. All TRC-based products are produced using its cell manufacturing system in centralized manufacturing facilities. The Company has one manufacturing site in Ann Arbor, and two contract facilities in Stuttgart, Germany and Bad Oeynhausen, Germany.
The Company is focused on utilizing its TRC technology to produce autologous cell-based products for use in regenerative medicine applications. Its clinical development programs are focused primarily on the utilization of its TRC technology for cardiac and vascular regeneration.
Cardiac Regeneration
As of June 30, 2009, 21 patients have been enrolled in the United States Phase II clinical trial and all five clinical sites are open for patient enrollment. In November 2008, the first patient was treated in the 40-patient IMPACT-DCM trial to evaluate the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient’s own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure.
Vascular Tissue Regeneration
In October 2008, the first 30 patients completed enrollment in the RESTORE-CLI trial, a United States Phase IIb prospective, controlled, randomized, double-blind, multi-center clinical trial to treat patients suffering from CLI. Patients are randomized into two patient groups to evaluate the safety and efficacy of VRCs in the treatment of CLI. As of June 30, 2009, 73 patients were enrolled in the RESTORE-CLI trial and 21 clinical sites are open for patient enrollment.
Bone Regeneration
In May 2008, the Company reprioritized its clinical development programs to primarily focus on cardiovascular applications. An initial 5 patient bone regeneration study was conducted at three centers in Spain under Ethical Committee approval.
The Company competes with Baxter, Genzyme, Johnson & Johnson, Miltenyi Biotec, Medtronic, Advanced Cell Technology, Aldagen, Angioblast, Arteriocyte, Bioheart, Athersys, Cytori Therapeutics, Gamida Cell, Geron, Mesoblast, Osiris Therapeutics and StemCells.

Board
http://www.reuters.com/finance/stocks/companyOfficers?symbol=ASTM.W

Fin.Data
http://www.reuters.com/finance/stocks/financialHighlights?symbol=ASTM.W
http://finance.yahoo.com/q/ks?s=ASTM

SEC
http://google.brand.edgar-online.com/?sym=ASTM

Linear Chart -- Semilog Chart
chart.ashx

chart.ashx


Owners & Short-data:
http://www.mffais.com/ASTM
http://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=ASTM
http://shortsqueeze.com/?symbol=ASTM

Options
http://quote.morningstar.com/Option/Options.aspx?sLevel=A&ticker=ASTM

Products
http://www.aastrom.com/ClinicalPrograms.cfm
http://www.aastrom.com/technology.cfm

I.R.
http://www.aastrom.com/investor.cfm

News
http://www.aastrom.com/releases.cfm
http://www.google.com/finance/company_news?q=NASDAQ:ASTM

F.o.L.
http://www.finanzaonline.com/forum/showthread.php?t=1094187
http://www.finanzaonline.com/forum/showthread.php?t=541676
http://www.finanzaonline.com/forum/showthread.php?t=462337
http://www.finanzaonline.com/forum/showthread.php?t=479968

I M O



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 

Allegati

  • SAL.VIjpg0.jpg
    SAL.VIjpg0.jpg
    120,9 KB · Visite: 332
  • SAL.VIjpg1.jpg
    SAL.VIjpg1.jpg
    114,8 KB · Visite: 316
  • SAL.VIjpg2.jpg
    SAL.VIjpg2.jpg
    79,5 KB · Visite: 265
  • SAL.VIjpg3.jpg
    SAL.VIjpg3.jpg
    120,2 KB · Visite: 263
Bcrx.

$@!V€ A TUTTI. Data and charts (only) for BCRX.

Chart ema-format: price replaced by exp.mov.aver. in daily frame 5/10/20 (thin-lines); in bold-lines three simple moving averages (daily 50/200/500).
Chart weekly-barrs-format: price as barrs in weekly frame with main simple moving averages.
Chart monthly-candles-format: price as candles in monthly frame.


BCRX

Site
http://www.biocryst.com/
BioCryst Pharmaceuticals, Inc. (BioCryst: 2190, Parkway Lake Drive, Birmingham AL 35244) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. The Company’s product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral formulation of the compound is in a Phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL). Additionally, forodesine HCl is being studied in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its another drug candidate, peramivir, is an inhibitor of influenza neuraminidase. Peramivir is in development for the treatment of influenza with two parenteral formulations, intramuscular (i.m.) and intravenous (i.v.). Its second generation PNP inhibitor, BCX-4, is in clinical trials.
PNP Inhibitors
PNP is an enzyme that plays a role in T-cell proliferation, because it is necessary to maintain normal DNA synthesis in human T-cells. Forodesine HCl is an investigational PNP inhibitor for the potential treatment of T-cell leukemias and lymphomas. The Company completed a Phase I/II clinical trial of forodesine HCl to determine the safety of repeat doses of an i.v. formulation of the drug in patients with B-ALL. BCX-4208 is a PNP inhibitor as a drug candidate for the treatment of T-cell mediated autoimmune diseases, including psoriasis, and transplant rejection. BCX-4208 has the ability to suppress PNP for longer periods of time.
Neuraminidase Inhibitor
Neuraminidase assists in the release and spread of the flu virus by breaking the chemical strands that hold the new viruses to the cell surface, allowing the replicated virus to spread and infect other cells. This process progresses until the host’s immune response can produce enough antibodies to bring the infection under control. Inhibiting the neuraminidase enzyme keeps new viruses attached to the cell surface, thereby preventing the spread of the virus and the further infection of other cells.
The Company competes with Eisai, GSK and Roche.

Board
http://www.reuters.com/finance/stocks/companyOfficers?symbol=BCRX.W

Fin.Data
http://www.reuters.com/finance/stocks/financialHighlights?symbol=BCRX.W
http://finance.yahoo.com/q/ks?s=BCRX

SEC
http://google.brand.edgar-online.com/?sym=BCRX

Linear Chart -- Semilog Chart
Automatic Charts
p.php

z
z

chart.ashx
p.php

chart.ashx
chart.ashx



Owners & Short-data:
http://www.mffais.com/BCRX
http://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=BCRX
http://shortsqueeze.com/?symbol=BCRX

Options
http://quote.morningstar.com/Option/Options.aspx?sLevel=A&ticker=BCRX

Products
http://www.biocryst.com/clinical_pipeline

I.R.
http://investor.shareholder.com/biocryst/index.cfm

News
http://investor.shareholder.com/biocryst/releases.cfm
http://www.google.com/finance/company_news?q=NASDAQ:BCRX

Competitors
http://www.reuters.com/finance/stocks/overview?symbol=4523.T
http://www.reuters.com/finance/stocks/overview?symbol=GILD.OQ
http://www.reuters.com/finance/stocks/overview?symbol=ROG.VX
http://www.reuters.com/finance/stocks/overview?symbol=GSK.L
http://finance.yahoo.com/q?s=RHHBY.PK

F.o.L.
http://www.finanzaonline.com/forum/showthread.php?t=919237

I M O



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 

Allegati

  • SAL.VIjpg3.jpg
    SAL.VIjpg3.jpg
    74 KB · Visite: 166
  • SAL.VIjpg2.jpg
    SAL.VIjpg2.jpg
    117,4 KB · Visite: 173
  • SAL.VIjpg1.jpg
    SAL.VIjpg1.jpg
    114,5 KB · Visite: 166
  • SAL.VIjpg0.jpg
    SAL.VIjpg0.jpg
    118 KB · Visite: 191
Dvax.

$@!V€ A TUTTI. Data and charts (only) for DVAX.

Chart weekly-barrs-format: price as barrs in weekly frame with main simple moving averages.


DVAX

Site
http://www.dynavax.com/
Dynavax Technologies Corporation (Dynavax: 2929 Seventh Street, Suite 100, Berkeley CA 94710), incorporated on August 29, 1996, is a biopharmaceutical company that discovers and develops products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The Company’s principal product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. Its pipeline of product candidate includes HEPLISAV; its Universal Flu vaccine; clinical-stage programs for hepatitis C and hepatitis B therapies, and preclinical programs partnered with AstraZeneca and GlaxoSmithKline (GSK). In January 2010, the Company announced the completion of the acquisition of Symphony Dynamo, Inc.
HEPLISAV
Dynavax has worldwide rights to HEPLISAV, which is based on the Company’s immunostimulatory sequences (ISS) that specifically target TLR9 to stimulate an innate immune response. This vaccine combines the Company’s 1018 ISS with hepatitis B surface antigen (HBsAg) manufactured in its Dynavax Europe facility in Dusseldorf, Germany. In September 2009, Dynavax initiated a Phase III trial in chronic kidney disease patients and in February 2010, it initiated a Phase III lot-to-lot consistency trial in adults over 40 years of age. As of December 31, 2009, over 2,500 individuals had been vaccinated with HEPLISAV. In clinical trial conducted, PHAST (Phase III HeplisAv Short-regimen Trial), HEPLISAV met its primary endpoint. The multi-center PHAST trial evaluated more than 2,400 subjects from 11 to 55 years of age in Canada and Germany. This Phase III trial randomized subjects three to one and evaluated a two-dose regimen of HEPLISAV administered at 0 and 1 month. Results showed 95.1% of subjects, who received two doses of HEPLISAV at 0 and 1 month developed protective antibody to hepatitis B when measured at 12 weeks. Data from this trial also demonstrate that subjects over 40 years of age receiving two doses of HEPLISAV over one month achieved a seroprotection rate of 92%. In September 2009, the United States Food and Drug Administration (FDA) removed the clinical hold on the Investigational New Drug (IND) application for individuals with chronic kidney disease.
Universal Flu Vaccine
The Company’s Universal Flu vaccine is in pre-clinical development and is designed to offer protection against influenza strains, as well reduce the dose of standard flu vaccine. The Company’s component, NP and M2e linked to its TLR9 agonist, is combined with the standard flu vaccine, which generates neutralizing antibodies.
SD-101
SD-101, the Company’s hepatitis C therapy, has completed a Phase Ib clinical trial. This therapy utilizes a Type C TLR9 agonist based on its ISS. SD-101 is designed to be used in combination with therapies to reduce hepatitis C virus (HCV) viral replication and induce a long-lasting immune response.
DV-601
DV-601 is the Company’s hepatitis B therapy and was in a Phase Ib clinical trial as of December 31, 2009. This treatment combines both the surface and core hepatitis B virus (HBV) antigens with an adjuvant.
AZD1419
As of December 31, 2009, the Company, together with AstraZeneca, was developing AZD1419, a candidate drug for asthma. AZD1419 utilizes its ISS for the treatment of allergic respiratory diseases, such as asthma.
DV1179
The Company’s DV1179 is a bifunctional inhibitor of TLR7 and TLR9. Dynavax and GlaxoSmithKline have entered into an alliance to discover, develop and commercialize DV1179 and other Toll-like Receptor (TLR) inhibitors for diseases, such as lupus, psoriasis and rheumatoid arthritis.

Board
http://www.reuters.com/finance/stocks/companyOfficers?symbol=DVAX.W

Fin.Data
http://www.reuters.com/finance/stocks/financialHighlights?symbol=DVAX.W
http://finance.yahoo.com/q/ks?s=DVAX

SEC
http://google.brand.edgar-online.com/?sym=DVAX

Linear Chart -- Semilog Chart
Automatic Charts
p.php

z
z

chart.ashx
p.php

chart.ashx
chart.ashx

CLAU automatic charts
big.chart


Owners & Short-data:
http://www.mffais.com/DVAX
http://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=DVAX
http://shortsqueeze.com/?symbol=DVAX

Options
http://quote.morningstar.com/Option/Options.aspx?sLevel=A&ticker=DVAX

Products
http://www.dynavax.com/pipeline.html

I.R.
http://investors.dynavax.com/index.cfm

News
http://investors.dynavax.com/newsevents.cfm
http://www.google.com/finance/company_news?q=NASDAQ:DVAX

Competitors
http://finance.yahoo.com/q?s=ILMN
http://finance.yahoo.com/q?s=LIFE
http://finance.yahoo.com/q?s=AFFX
http://finance.yahoo.com/q?s=CBMX
http://www.reuters.com/finance/stocks/overview?symbol=ABT.N
http://www.reuters.com/finance/stocks/overview?symbol=PFE.N

F.o.L.
http://www.finanzaonline.com/forum/showthread.php?t=980110
http://www.finanzaonline.com/forum/showthread.php?t=1092868
http://www.finanzaonline.com/forum/showthread.php?t=1092553
http://www.finanzaonline.com/forum/showthread.php?t=671809

I M O



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 

Allegati

  • SAL.VIjpg4.jpg
    SAL.VIjpg4.jpg
    119,3 KB · Visite: 212
Hska.

$@!V€ A TUTTI. Data and charts on HSKA.

Warning - same pattern of 2003: see moving averages 200 and 500 daily and see ema (5/10/20 daily) on 0.82 level.


HSKA [ NASDAQ Capital Market ] - 3760 Rocky Mountain Avenue, Loveland CO 80538.
SITE
http://www.heska.com/
Board
http://www.reuters.com/finance/stocks/companyOfficers?symbol=HSKA.W
FIN.-Data
http://www.reuters.com/finance/stocks/financialHighlights?symbol=HSKA.W
http://finance.yahoo.com/q/ks?s=HSKA
Owners & Short-data
http://www.mffais.com/HSKA
http://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=HSKA
http://shortsqueeze.com/?symbol=HSKA
Options
http://quote.morningstar.com/Option/Options.aspx?sLevel=A&ticker=HSKA
SEC
http://google.brand.edgar-online.com/?sym=HSKA
Competitors
http://finance.yahoo.com/q?s=ABAX
http://finance.yahoo.com/q?s=BAYRY.PK
http://finance.yahoo.com/q?s=IDXX
http://www.reuters.com/finance/stocks/overview?symbol=SYNB.PK
http://www.reuters.com/finance/stocks/overview?symbol=PFE.N
I.R.
http://www.heska.com/About-Heska/Investor-Relations.aspx
Short Data
http://shortsqueeze.com/?symbol=hska&submit=Short+Quote%99
Insiders
http://www.smartmoney.com/stock-quote/?story=insiders&symbol=hska

Linear Chart -- Semilog Chart
p.php

z
z

chart.ashx
p.php

chart.ashx
chart.ashx


Press
http://www.heska.com/About-Heska/Press-Center.aspx
http://www.google.com/finance/company_news?q=NASDAQ:HSKA
Main products
http://www.heska.com/Products/Lab-Systems.aspx
Using proven FUJIFILM technology, the DRI-CHEM 4000 chemistry analyzers is designed to deliver accurate results while maximizing testing flexibility. Choose from individual tests and pre-packaged cpanels. Easy to use features like automated dilution, stackable slide racks and multiple sampling options make the DRI-CHEM 4000 an important part of any in-clinic lab.
The HemaTrue analyzer delivers excellent precision and correlation (accuracy) across a wide range of values. In a recent study of over 300 dogs, cats,and horses, HemaTrue analyzers provided results virtually identical to those of a reference lab, in only 55 seconds and with only 20 µL (about one drop) of blood. Ease-of-use features include a color LCD touch-screen, step-by-step instruction screens, an on-board blood mixer, and an integrated bar code reader.
The New DRI-CHEM 7000 analyzer offers the sampling and testing flexibility of the DRI-CHEM 4000 plus additional advantages that increase efficiencies for high-volume clinics. Run 5 individual comprehensive panels in 30 minutes, 5 individual Pre-surgical Panels in 16 minutes, and load 5 patient samples at one time. In addition, the STAT Sample feature allows for efficient processing of samples in cases of emergency. The high-throughput DRI-CHEM 7000 meets the needs of even the busiest practices.
The NEW VitalPath analyzer represents a major advancement in blood gas and electrolyte analysis. In just 3 easy steps, the VitalPath delivers accurate results in just 50 seconds for 35 parameters. Requiring as little as 60 µL of whole blood, serum or plasma, the VitalPath offers very flexible sampling options and can be customized to the needs of any clinic.
http://www.heska.com/Products/ALLERCEPT/ALLERCEPT.aspx
With routine allergy cases, general practitioners can test and treat with confidence. Heska will guide you through the process providing:
* Easy-to-read results summary within 48 hours of receiving the sample
* Recommendation for precise allergen-specific immunotherapy treatment
* Free case consultation with veterinary professionals in Heska's Medical and Technical Consultation Group
http://www.heska.com/Products/Intranasal-Vaccines/Feline-UltraNasal-Vaccines.aspx
Heska's Feline UltraNasal Vaccines provide safe, needle-free protection against the most prevalent causes of feline upper respiratory disease and panleukopenia. Heska's Feline UltraNasal Vaccines provide rapid immunity in both cats and kittens with a single 0.2-ml dose and without the risk of injection site sarcoma.
SAFE
* Laboratory studies demonstrate Feline UltraNasal ® Vaccines provide effective immunity against feline rhinotracheitis virus, feline calicivirus and panleukopenia virus.
* The safety of the vaccines also was tested. The most common clinical sign observed was transient sneezing. Vaccinated cats recovered without incident.
* FVRCP vaccines administered subcutaneously induce a statistically signifcant antibody response against kidney cells. The intranasally administered Feline UltraNasal® Vaccines do not. Currently, the relationship between these antibodies and feline kidney disease is not known and is the subject of ongoing research.
EFFECTIVE
* To immunize cats against upper respiratory disease, a 0.2-mL dose of Heska’s FVRC vaccine may be administered to kittens as young as 12 weeks of age to provide protective immunity against feline rhinotracheitis and feline calicivirus.
* For protection against upper respiratory disease and panleukopenia virus, a 0.2-mL dose of Heska’s FVRCP vaccine may be administered to cats 12 weeks of age or older. If cats are vaccinated at less than 12 weeks of age, a second vaccination should be administered at 12–16 weeks of age. Annual re-vaccination is recommended.
* When compared to unvaccinated control cats, vaccinated cats had evidence suggesting early protection against virulent herpesvirus-1 challenge as early as two days post-vaccination with signifcant protection being detected by four days post-vaccination. Data generated in another study suggested vaccination of previously uninfected cats via the intranasal route may prevent the subsequent development of a rhinotracheitis virus carrier state following challenge with virulent feld virus, at least in the short term.
http://www.heska.com/Products/Heartworm.aspx
Solo Step CH and Solo Step FH Heartworm Tests are lateral flow immunoassays for the detection of canine antigens or feline antibodies in serum, plasma or anti-coagulated whole blood. When only a heartworm test is warranted, Solo Step tests provide an inexpensive and extremely accurate one-step process for heartworm detection.
http://www.heska.com/Products/Renal-HealthScreen/ERD-HealthScreen.aspx
Detecting albumin at a sensitivity up to 30X that of dipsticks, Canine and Feline E.R.D.-HealthScreen Tests are the most sensitive measure of kidney damage available, and can be a reliable and early indicator of hidden diseases. With results in less than 5 minutes, these tests are an excellent tool for monitoring the severity, treatment and progression of kidney damage.
EARLY RENAL DAMAGE DETECTION FOR DOGS AND CATS
* The ONLY In-Clinic Urine Test to Detect Microalbuminuria: Detects kidney insult prior to BUN/Creatinine indices.
* Results in Less Than 5 Minutes
* Easy to Read: Semi-quantitative. Shows negative, low, medium, high and very high positive test results.
* Extremely Accurate: Highly sensitive and specifc in detecting the presence of albuminuria that could be caused by many common infammatory, infectious, metabolic and neoplastic diseases.
-) Monoclonal antibody specific to species.
* Excellent Monitoring Tool: Track disease severity, treatment success, and progression of kidney damage.
-) Add E.R.D.-HealthScreen Tests to Annual Health Exams, and Pre-Surgical Diagnostic Work-Ups.
-) Monitor breeds at risk of renal disease and those on medications that may affect the kidney.
http://www.heska.com/Products/Supplements.aspx
-) Heska's ThyroMed Tablets make it easier for pet owners to administer daily treatment for hypothyroidism.
-) Heska's F.A. Granules provide support for a healthy skin and coat in a flavor base pets love.
http://www.heska.com/Products/IV-Pumps/Vet-IV-Infusion-Pump.aspx
Find out why thousands of customers love Heska's Vet/IV Pump. The unit is easy to use, can be operated on battery or AC power, and can be mounted on a cage or IV pole. Weighing only 2.6 pounds, the Vet/IV Pump supports three pressure settings and can be programmed for very small to very large volumes with rate and time or rate and volume to be infused.
http://www.heska.com/Products/Dx-Lab-Services/Dx-Lab-Services.aspx
Heska’s Veterinary Diagnostic Laboratory (VDL) provides veterinary clinics with an extensive menu of diagnostic tests ranging from our unique proprietary ALLERCEPT® serum IgE allergy tests, to routine chemistry and hematology profiles, to advanced PCR tests.
In addition to providing accurate, timely, and reliable results, Heska Veterinary Diagnostic Laboratory employs an on-site team of veterinary professionals trained to assist you with case consultations, test interpretations, diagnosis and treatment options. Following strict quality control and quality assurance measures, Heska’s Veterinary Diagnostic Laboratory provides veterinarians the ability and support to confidently practice better medicine.
Some Tickerspy Related Indexes:
http://www.tickerspy.com/member.php?mid=54067&pid=79691
http://www.tickerspy.com/member.php?mid=56465&pid=81997

Heska Corporation, incorporated in 1988, develops, manufactures, markets, sells and supports veterinary products. The Company’s focus is on the canine and feline companion animal health markets. The Company has two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by the Company, as well as through independent third-party distributors and other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals including small mammals and fish. All OVP products are sold by third parties under third party labels.
Core Companion Animal Health Segment
The Company offers a line of veterinary diagnostic and other instruments. It also markets and sells consumable supplies for these instruments. Its veterinary instruments include Handheld Blood Analysis, Blood Chemistry, Hematolog and IV Pumps. The i-STAT 1 Handheld Clinical Analyzer is a handheld instrument that provides analysis of critical electrolyte, blood gas, chemistry and basic hematology results with whole blood. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is an easy-to-use blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to provide regulated infusion of fluids, drugs or nutritional products for their patients.
The Company markets and sells heartworm diagnostic tests for both dogs and cats. SOLO STEP CH for dogs and SOLO STEP FH for cats are available in point-of-care, single use formats that are used by veterinarians. It also offers SOLO STEP CH Batch Test Strips, a point-of-care antigen detection test for dogs that allows veterinarians in larger practices to run multiple samples at the same time. Its E.R.D.-HEALTHSCREEN Canine Urine Test and E.R.D.-HEALTHSCREEN Feline Urine Test are in-clinic immunoassay tests designed to detect microalbuminuria, the sensitive indicator of renal damage.
The Company’s ALLERCEPT Definitive Allergen Panels provide the determination of which the Company is aware of the specific allergens, to which an animal, such as a dog, cat or horse, is reacting. The test panel consists primarily of various pollen, grass, mold, insect and mite allergens. The test results serve as the basis for prescription ALLERCEPT Allergy Treatment Sets. It sells ERD Reagent Packs used to detect microalbuminuria, the indicator of renal damage, to Antech Diagnostics, the laboratory division of VCA Antech, Inc., for use in its veterinary diagnostic laboratories.
Other Vaccines, Pharmaceuticals and Products Segment
The Company manufactures biological and pharmaceutical products for a number of other animal health companies. It manufactures products for animals including small mammals. The Company’s offerings range from providing complete turnkey services which include research, licensing, production, labeling and packaging of products to providing any one of these services as needed by its customers, as well as validation support and distribution services.
The Company competes with IDEXX, Abaxis, Inc. and Synbiotics Corporation.


N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
Kool.

KOOL-warning.
Company jump on ema/50-200.
On bull-cross of 0.785-level (in ema-format), target 0.97/1.03-area ???

z
z


big.chart


$@!V€ A TUTTI.

Aggiornamento chart KOOL.

Chart I - prezzi sostituiti dalla ema daily 5/10/20; ad esse sovrapposte le tre medie mobili semplici daily 50/200/500.

Chart II - zoom.

Chart III - metodica delle due envelopes (breve-medio vs. lungo termine).

Chart IV - monthly candle con stupefacente nov.2008 includente tutte le successive (price-space: 0.93 $; up-target 2.17 $; down %-target 0.07/0.08 $).

Chart V - daily candle con le tre medie primarie semplici (50/200/500), il corposo gap-down ancora parzialmente vacuo (nov.2008), ed il full-stock. di lungo termine.



KOOL - pure player
sub-sector: stem (cord, blood); bank, clinical stem-use technology; CNS, liver, bone (veterinay also), dermis, circulatory-sist.

http://www.thermogenesis.com/
ThermoGenesis Corp. [2711 Citrus Road, Rancho Cordova CA 95742], incorporated in July 1986, designs, develops and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells, wound healing proteins or growth factors from a single unit of cord blood or the patient’s own blood in less than one hour. Initially, the Company developed medical devices for ultra rapid freezing and thawing of blood components, which the Company manufactures and distributes to blood banks and hospitals. The Company’s business model is based on the sale of medical devices and the recurring revenues generated from the companion single-use, sterile disposable products. Its products are sold in 34 countries throughout the world. The Company’s end user customers include private and public cord blood banks, surgeons, hospitals and research institutions.
The Company provides the tools necessary for the collection, separation, expansion, storage and delivery of stem cells from adult tissue sources, including cord blood, bone marrow, (later) adipose and placenta. These tools are being used by health care providers in both the laboratory and point of care setting. It provides tools and technologies to enable separation and cryopreservation of biological fluids, including peripheral, bone marrow and umbilical cord blood.
The AutoXpress Platform (AXP) is a medical device with an accompanying disposable bag set that isolates and retrieves stem cells from umbilical cord blood. The AXP provides cord blood banks with a system to isolate and capture adult stem cells with lower labor costs and a reduced risk of contamination. The Company’s market for the AXP includes both private and public cord blood banks. The product is an automated, closed, sterile system that volume-reduces cord blood to a user defined volume in 30 minutes, able to retain over 97% of the mononuclear cells. The MarrowXpress, an extension of the AXP, isolates and retrieves stem cells from bone marrow aspirate and its initial application is for the preparation of cells for regeneration of bone in spinal fusion procedures. The product is an automated, closed, sterile system that volume-reduces blood from bone marrow to a user-defined volume in 30 minutes, while retaining over 90% of the mononuclear cells.
The BioArchive System is an automated cryogenic system used in stem cell therapy to cryopreserve and archive stem cells for future transplant and treatment. Over 200 BioArchive Systems have been purchased by over 90 umbilical cord blood stem cell banks in over 30 countries worldwide to archive, cryopreserve and store stem cell preparations extracted from human placentas and umbilical cords for future use. The BioArchive System can store over 3,600 stem cell samples. The Res-Q product is also used for bone marrow stem cell processing and was launched in July 2009. The Res-Q can be used in a clinical laboratory or can be used inter-operatively at the point of care. The technology is a centrifuge-based disposable device designed for the isolation and extraction of specific stem cell populations at the point of care. Res-Q is a product, which achieves a higher recovery rate of stem cells from bone marrow.
The Company’s Thermoline product line includes the ultra-rapid plasma Thermoline Freezer and ultra-rapid plasma Thermoline Thawer. It offers two models of plasma freezers, which vary primarily by capacity and condenser type. The Thermoline freezer optimizes plasma freezing through its liquid heat transfer and uniform freezing technologies that can freeze units of blood plasma in approximately 30 minutes. These products are suited for medium to large laboratories. It also offers three models of blood components thawers, which vary primarily by capacity. The product’s flexible membrane technology allows for a closed thawing system. These instruments can be used for rapid (less than 12 minutes) homogeneous thawing of plasma and glycerolized frozen red blood cells. The CryoSeal Fibrin Sealant (CryoSeal) System is an automated system used to prepare an autologous hemostatic surgical sealant from a patient’s own blood or from a single donor in approximately one hour. The CryoSeal serves the wound care market.
The Company competes with BioSafe, BioE, COBE, Ficoll Harvest, BioMet, Chart, Taylor Wharton, Helmer, Thermo Fisher Scientific, Harris and Jewett.

Board
http://www.reuters.com/finance/stocks/companyOfficers?symbol=KOOL.W

Fin.Data
http://finance.yahoo.com/q/ks?s=KOOL
http://www.reuters.com/finance/stocks/financialHighlights?symbol=KOOL.W

SEC
http://google.brand.edgar-online.com/?sym=KOOL

Chart
chart.ashx


Products & Trials
http://www.thermogenesis.com/solutions.aspx

Owners & Short-data:
http://www.mffais.com/KOOL
http://moneycentral.msn.com/investor/invsub/ownership/ownership.asp?Symbol=KOOL
http://shortsqueeze.com/?symbol=KOOL

Options
http://quote.morningstar.com/Option/Options.aspx?sLevel=A&ticker=KOOL

I.R.
http://www.thermogenesis.com/investors.aspx

News
http://www.thermogenesis.com/pr-news-and-events.aspx
http://www.google.com/finance/company_news?q=NASDAQ:KOOL

F.o.L.
http://www.finanzaonline.com/forum/showthread.php?t=1071369
http://www.finanzaonline.com/forum/showthread.php?t=834154
http://www.finanzaonline.com/forum/showthread.php?t=770067



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra: http://www.finanzaonline.com/forum/showpost.php?p=23548136&postcount=66
New F.o.L. Order: http://www.finanzaonline.com/forum/showpost.php?p=24105781&postcount=38
.
 
Cryptococcus gattii

$@!V€ A TUTTI. Uno dei più attivi "ricercatori" finanziari del FoL in merito a biotech., ha recentemente segnalato la news relativa un


possibile out-break in America su una possibile infezione grave veicolata da un Micote o fungo, noto come Cryptococcus gattii (Basidiomycota: Tremellales).

Al fine di approfondire la faccenda, predispongo alcuni links

Cryptococcus gattii

Articolo scientifico sulla questione dell'attuale out-break - html
Articolo scientifico sulla questione dell'attuale out-break - pdf

Articolo sul precedente evento (2007) di out-break

Sito di riferimento su C. gattii

Genomica di Cryptococcus

Articolo sulle modificazioni in Cryptococcus


Cryptococcus.jpg
new-killer-airborne-fungus_19371_600x450.jpg

fetchObject.action



DRUGS

Amphotericin B
220px-Amphotericin_b.gif


Flucytosine
220px-Flucytosine.svg.png


Fluconazole
160px-Fluconazole-from-xtal-3D-balls.png







I M O

N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
Ultima modifica:
Full Oscillator.

$@!V€ A TUTTI. Data and charts on a new momentum instrument: The Full Oscillator.

L'oscillatore è stato ideato durante le WSOP del 2003, nella fase di passaggio tra il live-poker e l'on-line poker.
Come si evince dal chart attached, l'oscillatore permette di individuare in full e validare in scala i turn bear vs. bull del mercato, con un sincronismo su base 5-minute barrs on intraday frame.
L'oscillatore viene regolarmente utilizzato nella Sal.Vi main trading olistic semantic station per eseguire accurate previsioni sulla azienda di dissalazione che tutto il mondo gli invidia e che migliaia di traders seguono giarnalmente.
L'oscillatore deve essere usato in combine con altre metodiche intrusive e/o invasive al fine di meglio ottenere una view sullo scenario eicosaedristico più plausibile, dal punto di vista endoergonico.

Il settaggio è molto semplice ed è stato recentemente codificato da P.Ivey:
per ottenere il 90% di gain, la K-line deve essere tarata su frame 3 mentre la A-line su frame 2
per ottenere il 99% di gain, la K-line deve essere tarata su frame 2 mentre la A-line su frame 3

Si precisa che i market makers hanno eseguito una migrazione dalla piattaforma Full Oscillator based a quella Roy.Scale; pertanto si sconsiglia di assumere posizioni contro il mercato e di foldare il chart in caso di view opposta.

Il service-pak viene prodotto dalla Lesotho & Swazyland Central Bank e distribuito dalla PTEK e dalla PartyGaming

Il noto settimanale di scandalistica finanziaria 2k-goodnews, ha recentemente affermato che questo oscillatore viene utilizzato in tecniche tantriche di denudazione delle traders con la sola imposizione degli spread-reverse 2X e 69-inside da parte del Sal.Vi.

Nel service pak si troveranno i seguenti gadget algoritmici:
-) i fondi del caffè di Coffeman
-) un mattore di DIGA
-) un coltello per karakiri durante la lettura dei charts in doppio leverage e quintuplo libor-indicators del Sal.Vi
-) una granata della II W.W. pre-innescata per cessare i tentativi di comprensione degli RW-chart
-) OSINOD-imprecations vs. SirWildman
-) 14 massimi fuori conteggio di Celeron
-) 144 dildo automatici della finviz usati da Sal.Vi durante le analisi dei PGM
-) 700.000 charts del Sal.Vi sui metalli preziosi
-) uno stecco di liquirizia alsaziana prodotto dalla STEC
-) una caramella al latte prodotta dalla MU
-) 7 piani energetici by Obama
-) 11 riforme sanitarie by Obama
-) 89 riforme della pubblica istruzione 2009.
-) una vancanza in Grecia con Claudiano.


n.b.: il ben noto millenary chart è stato redatto con l'ausilio del Full Oscillator e altri 1023 indicatori. L'indicatore è pandemic-virus free.


I M O



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 

Allegati

  • SAL.VIjpg5.jpg
    SAL.VIjpg5.jpg
    122 KB · Visite: 319
BIO2❤12&More(Frattali,Frattaglie,Fritt at e,Franchige,Franchi,Futures,Féssy)...

logo.gif
KOOL - pure player
sub-sector: stem (cord, blood); bank, clinical stem-use technology; CNS, liver, bone (veterinay also), dermis, circulatory-sist.
ThermoGenesis Corp. [2711 Citrus Road, Rancho Cordova CA 95742], incorporated in July 1986, designs, develops and commercializes medical products that enable the collection, processing and cryopreservation of stem cells and other cellular tissues used in the practice of regenerative medicine. Its products automate the volume reduction and cryopreservation process of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. As of June 30, 2011, the Company sells its products in 35 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. The Company provides products and technologies for separation and cryopreservation of biological fluids including umbilical cord blood, peripheral and bone marrow in a format. These products and technologies are designed for use in the laboratory as well as point of care.
The AXP is a medical device with an accompanying disposable bag set that isolates and retrieves stem cells from umbilical cord blood. The AXP provides cord blood banks with an automated system to enrich adult stem cells combined with lower labor costs and a reduced risk of contamination. The AXP System retains over 97% of the mononuclear cells (MNC’s). The AXP device contains flow control optical sensors that achieve precise separation. Its market for the AXP includes both private and public cord blood banks.
The MarrowXpress or MXP, an extension of the AXP, and its accompanying disposable bag set isolates and concentrates stem cells from bone marrow aspirate and its initial application is for the preparation of cells for regeneration of bone in spinal fusion procedures. The product is an automated, closed, sterile system that volume-reduces blood from bone marrow to a user-defined volume in 30 minutes, while retaining over 90% of the MNCs. The MXP contains flow control optical sensors that achieve precise separation. The Res-Q 60 BMC product is a centrifuge-based disposable device designed for the isolation and extraction of specific stem cell populations from bone marrow. The Res-Q 60 PRP, is designed to be used for the safe and rapid preparation of autologous PRP from a small sample of blood at the point of care.
The BioArchive System is a robotic cryogenic medical device used to cryopreserve and archive stem cells for future transplant and treatment. BioArchive Systems have been purchased by over 110 umbilical cord blood banks in over 35 countries to archive, cryopreserve and store stem cell preparations extracted from human placentas and umbilical cords for future use. The BioArchive System is designed to store over 3,600 stem cell samples. It is the only fully-automated, commercially available system that integrates controlled-rate freezing, sample management and long term cryogenic storage in liquid nitrogen. The robotic storage and retrieval of these stem cell units improves cell viability, provides precise inventory management and minimizes the possibility of human error.
The ThermoLine product line includes the ultra-rapid plasma ThermoLine Freezer and ultra-rapid plasma ThermoLine Thawer. The Company offers two models of plasma freezers, which vary primarily by capacity and condenser type. The ThermoLine freezer optimizes plasma freezing through its liquid heat transfer and uniform freezing technologies that can freeze units of blood plasma in approximately 30 minutes. These products are suited for medium to large laboratories. The CryoSeal System is an automated system serving the wound market used to prepare an autologous hemostatic surgical sealant from a patient’s own blood or from a single donor in approximately one hour.
The Company competes with BioSafe/Sepax, BioE, Pall Corporation, Chart Industries, Taylor-Wharton, COBE Spectra, Ficoll-Paque, Terumo Cardiovascular Systems/SmartPReP2, Biomet/MarrowStim, Biomet/GPS III and the BioCUE.
Profile & Board -- REUT-Fin.Data -- YHOO Fin.Data -- FINVIZ-Fin.Data -- BARCH-Fin.Data -- GOOG Fin.Data -- ZACK Fin.Data -- Y-Fin.Data
SEC -- Owners -- Insiders -- Short-data -- Options -- Analysts -- NewsByGOOG -- NewsByKOOL -- Products --I.R.

chart
chart

chart.ashx
chart.ashx

big.chart

big.chart

big.chart

big.chart


Sorry for my bad English. I hope that this post is at least minimally useful.
☻/ ❖ Globo.pk, Alert 2.O !!! ❖
/▌
/|
Tuned on main trend, but follows short-medium term signs from underlying prices, for a correct & real-time set-up.
It is very important do not anticipate the main trend of the underlying financial instruments.

Ⓘℳ☢ ℬɣ $@❣♆¥ ►►♥®█║▌│││█║℠™║▌║▌▌║█©❤◀◀
₭€$AⅅⅅhAPhA'pe'₭AℳℙA' ℬunda-ℬunda €MP¥R€ ❣❣❣
 
Ultima modifica:
Signori qualcosa sta muovendo in questo mese alcune biotech. pandemic-stocks (see C.gatti in quoted).
Banali movimenti tecnici e/o preparazione per qualcos'altro ?

chart.ashx
chart.ashx

chart.ashx
chart.ashx

chart.ashx
chart.ashx

chart.ashx
chart.ashx



$@!V€ A TUTTI. Uno dei più attivi "ricercatori" finanziari del FoL in merito a biotech., ha recentemente segnalato la news relativa un possibile out-break in America su una possibile infezione grave veicolata da un Micote o fungo, noto come Cryptococcus gattii (Basidiomycota: Tremellales).

Al fine di approfondire la faccenda, predispongo alcuni links

Cryptococcus gattii

Articolo scientifico sulla questione dell'attuale out-break - html
Articolo scientifico sulla questione dell'attuale out-break - pdf

Articolo sul precedente evento (2007) di out-break

Sito di riferimento su C. gattii

Genomica di Cryptococcus

Articolo sulle modificazioni in Cryptococcus


Cryptococcus.jpg
new-killer-airborne-fungus_19371_600x450.jpg

fetchObject.action



DRUGS

Amphotericin B
220px-Amphotericin_b.gif


Flucytosine
220px-Flucytosine.svg.png


Fluconazole
160px-Fluconazole-from-xtal-3D-balls.png







I M O

N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
ILMN (Nasdaq) - Illumina

$@!V€ A TUTTI. Data and charts on ILMN.

ILMN data.

Site
Illumina, Inc. (Illumina: 9885 Towne Centre Drive, San Diego CA 92121), incorporated in April 1998, is a developer, manufacturer, and marketer of integrated systems for the analysis of genetic variation and biological function. The Company provides a line of products and services that serve the sequencing, genotyping, and gene expression markets. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Illumina develops and commercializes sequencing technologies used to perform a range of analyses, including de novo sequencing, whole genome re-sequencing, gene expression analysis, and small RNA analysis. Its product and service offerings also include solutions for single-nucleotide polymorphism (SNP) genotyping, copy number variation (CNV), deoxyribonucleic acid (DNA) methylation studies, gene expression profiling, and low-multiplex analysis of DNA, small ribonucleic acid (RNA), and protein.
Sequencing Technology
In its DNA sequencing systems, the Company applies the SBS biochemistry on microscopic islands of DNA, referred to as DNA clusters. Each cluster starts as a single DNA molecule fragment, typically a few hundred bases long, attached to the inside surface of a flow cell. It then uses an amplification biochemistry to create copies of each starting molecule. As the copies are made, they are covalently linked to the surface, so they cannot diffuse away. After a number of cycles of amplification, each cluster might have approximately 1,000 copies of the original starting molecule, but still be only about a micron (one-millionth of a meter) in diameter. By making so many copies, the fluorescent signal from each cluster is significantly increased. As the clusters are so small, hundreds of millions of clusters can be independently formed inside a single flow cell. This large number of clusters can then be sequenced simultaneously by alternate cycles of SBS biochemistry and fluorescent imaging. Sequence reads are aligned against a reference genome and genetic differences are called using specially developed data analysis software.
BeadArray Technology
Illumina’s BeadArray technology combines microscopic beads and a substrate in a simple manufacturing process to produce arrays that can perform many assays simultaneously, enabling large-scale analysis of genetic variation and biological function. Its BeadArray technology consists of two-micron silica beads that self-assemble into microwells etched into an array substrate. It has deployed its BeadArray technology in two different array formats, the Array Matrix and the BeadChip.
VeraCode Technology
Illumina’s VeraCode technology platform leverages the power of digital holographic codes to provide a robust detection method for multiplex assays requiring high precision, accuracy, and speed. Each VeraCode bead type is inscribed with a digital holographic code to designate and track the specific analyte or genotype of interest throughout the multiplex reaction. When excited by a laser, each VeraCode bead emits a code image, allowing for quick and specific detection by Illumina’s BeadXpress Reader System.
The Company competes with Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Complete Genomics, Inc.; General Electric Company; Helicos BioSciences Corporation; Life Technologies Corporation; Luminex Corporation; Pacific Biosciences, Inc.; Roche Diagnostics Corp.; Sequenom, Inc., and Qiagen N.V.
Board
Fin.Data
Fin.Data
SEC
Owners
Short-data
Short-data
Options
News by GOOG
News by company
I.R.
Products


ILMN charts [ Linear Chart -- Semilog Chart ]

Automatic intraday charts
p.php

z
z

Automatic charts in superior frames
chart.ashx

Automatic chart ema-format: price replaced by dots (daily close), with short term exp.mov.aver. 5/10/20, and some medium-long term exp.mov.aver.
big.chart


I M O



N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
Cancer Immunotherapy Index

$@!V€ A TUTTI. Alcuni interessanti links su un indice privato basato su company coinvolte nella immunoterapia tumorale. C.I.I.

cancer_immunotherapy_index.gif


SITE
PORTFOLIO
PRESS
TRIALS

see also Tickerspy-portfolio

Automatic charts ema-format: price replaced by dots (daily close), with short term exp.mov.aver. 5/10/20, and some medium-long term exp.mov.aver.
big.chart

big.chart
big.chart

big.chart
big.chart

big.chart
big.chart

big.chart
big.chart

big.chart
big.chart





N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order
 
WARNING for BCRX: coppa set.2007/set2009
 
BCRX .......... see 2007/2009 ...... a perfect cup ready to ... implode vs. explode ........ follow
 
Gern.

$@!V€ A TUTTI. Data and charts (only) on GERN.

GERN data.
no pure player (oncology also)
sub-sector: stem (embryo); heart, pancreas, bones

Site
Geron Corporation (Geron:230 Constitution Drive, Menlo Park CA 94025), incorporated on November 29, 1990, is a biopharmaceutical company that is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company is advancing telomerase targeted therapies, including an anti-cancer drug and a cancer vaccine, through multiple clinical trials. Geron also develops human embryonic stem cell (hESC)-based therapeutics. The Company is developing anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines. Geron is also researching compounds that transiently activate telomerase in senescent cells to restore cell function for the treatment of injuries and chronic diseases.
Geron has designed and synthesized a special class of short-chain nucleic acid molecules, known as oligonucleotides, which target the template region, or active site, of telomerase. Its work has focused on two of these oligonucleotides, called GRN163 and GRN163L, and it has demonstrated that they have potent telomerase inhibitory activity at low concentrations in biochemical assays, various cellular systems and animal studies.
The Company’s compounds GRN163 and GRN163L are direct enzyme inhibitors, not antisense compounds. They are smaller (lower molecular weight) than typical antisense compounds or other oligonucleotide drug candidates. Both compounds use a special thiophosphoramidate chemical backbone. GRN163L is a 13-mer oligonucleotide N3-- P5 thio-phosphoramidate (NPS oligonucleotide) that is covalently attached to a C16 (palmitoyl) lipid moiety. GRN163L binds directly with high affinity to the template region of the ribonucleic acid (RNA) component of human telomerase (hTR), which lies in the active or catalytic site of hTERT, the telomerase reverse transcriptase. GRN163L binding to hTR results in direct, competitive inhibition of telomerase enzymatic activity. The Company owns the rights to the telomerase antigen and its use in therapeutic vaccines.
Geron has developed several assays for the detection of telomerase, which are based on its activity or the presence of its RNA or protein components. The assay is the Telomeric Repeat Amplification Protocol assay, which can be used to detect telomerase activity in human tissue or cells, including clinical samples. The second-generation assays detect the presence of hTR and human telomerase reverse transcriptase hTERT in human tissues and body fluids.
The Company is researching drug candidates to treat various degenerative diseases by the controlled activation of telomerase. The Company’s majority-owned subsidiary in Hong Kong TA Therapeutics, Ltd. (TAT), was established to commercially develop products that utilize telomerase activator drugs to restore the regenerative and functional capacity of cells in various organ systems that have been impacted by senescence, injury or chronic disease. The Company own 75% of TAT and Biotechnology Research Corporation (BRC) owns 25%.
Geron has developed methods to grow, maintain, and scale the culture of undifferentiated hESCs that use feeder cell-free and serum-free media with chemically defined components.
The Company has developed cryopreserved formulations of hESC-derived cells to enable its business model of delivering on demand cells for therapeutic use. As of December 31, 2009, the Company and its collaborators are testing six different hESC-derived therapeutic cell types in animal models. In five of these cell types, Geron has demonstrated efficacy, as evidenced by durable engraftment or functional improvements of the treated animals.
Geron’s second hESC product, GRNCM1, is a population of cardiomyocytes, the contractile cells of the heart, which is intended for the treatment of patients with myocardial disease. It has also has made substantial progress in deriving pancreatic islet ß cells for diabetes and dendritic cells for two applications, including cancer immunotherapy and graft acceptance (to prevent immune rejection of the other cell types used in therapeutic applications). With the collaborators in the United Kingdom at the University of Edinburgh, the Company is deriving osteoblasts for osteoporosis, chondrocytes for osteoarthritis and hepatocytes for liver failure and metabolism and toxicity testing of drug compound.
The Company has derived insulin-producing cells from hESCs and is working to improve the yield of islet cells and characterize their secretion of insulin in response to glucose.
Geron is transplanting the islets to animal models of diabetes. Geron’s nuclear transfer technology can be used for applications in agriculture. Its nuclear transfer technology can be applied to clone animals that have been genetically engineered to produce proteins for human therapeutic or industrial use. The Company’s nuclear transfer technology can be used for applications in xenotransplantation to create animals whose cells, tissues or organs could be used in human organ transplantation settings. Geron has granted a number of licenses to its nuclear transfer technology to companies who are utilizing it for applications in agriculture and production of biologicals.
Board
Fin.Data
Fin.Data
SEC
Owners
Short-data
Short-data
Options
News by GOOG
News by company
I.R.
Products
Technology
Trials

F.o.L.
http://www.finanzaonline.com/forum/showthread.php?t=1065228
http://www.finanzaonline.com/forum/showthread.php?t=828248

I M O
N.B.: per trasparenza si comunica che lo scrivente potrebbe possedere, direttamente e/o indirettamente, quote degli strumenti finanziari in oggetto o ad essi correlati. Non si forniscono pertanto in alcun modo, raccomandazioni e/o segnali di vendita-acquisto sugli strumenti finanziari in oggetto o ad essi correlati.
Disclaimer manthra - New F.o.L. Order


GERN charts [ Linear Chart -- Semilog Chart ]

Automatic intraday charts
p.php
z

Automatic charts in superior frames
chart.ashx

big.chart

big.chart


Automatic chart ema-format: price replaced by short term exp.mov.aver. 5/10/20, and some medium-long term exp.mov.aver.
big.chart

big.chart


Attached chart in ema-format: price replaced by averaged [(O+C+H+L)/4] exp.mov.aver. in daily frame 5/10/20 in thin continuous lines, and in daily frame 50/200/500 in bold continuous lines; in not-continuous-line daily averaged exp.mov.aver. 1000.
Attached chart in average-indicators-format: two-envelopes method (blu-envel. as short-term vs. red-envel. as long-term), MACD, PPO, TRIX in medium-term frame and price in daily ema-5.
Attached chart in weekly-candles-format: price as candles in weekly frame with main ema (10/40/100-weekly = 50/200/500-daily, about) and with indicator of foundamental and technical data.
Attached chart in monthly-candles-format: price as candles in monthly frame.
 

Allegati

  • SAL.VIjpg0.jpg
    SAL.VIjpg0.jpg
    116 KB · Visite: 154
  • SAL.VIjpg1.jpg
    SAL.VIjpg1.jpg
    110 KB · Visite: 159
  • SAL.VIjpg2.jpg
    SAL.VIjpg2.jpg
    119,3 KB · Visite: 146
  • SAL.VIjpg3.jpg
    SAL.VIjpg3.jpg
    97,1 KB · Visite: 147
  • SAL.VIjpg4.jpg
    SAL.VIjpg4.jpg
    60,8 KB · Visite: 144
Indietro